KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Dynamic change in Epstein-Barr virus DNA predicts prognosis in early stage natural killer/T-cell lymphoma with pegaspargase-based treatment: long-term follow-up and biomarker analysis from the NHL-004 multicenter randomized study.

Huijuan Zhong, Shu Cheng, Jie Xiong, Jiayi Chen, Rongji Mu, Haoxu Yang, Hongmei Yi, Qi Song, Hao Zhang, Yu Hu, Guohui Cui, Juying Wei, Xi Zhang, Bing Xu, Wenbin Qian, Xiaobing Huang, Ming Hou, Feng Yan, Xin Wang, Yongping Song, Yuanhua Liu, Xuejun Ma, Jianda Hu, Fei Li, Chongyang Wu, Junmin Chen, Li Yu, Ou Bai, Jingyan Xu, Zunmin Zhu, Li Liu, Xin Zhou, Li Huang, Yin Tong, Ting Niu, Depei Wu, Xufeng Jiang, Chaofu Wang, Binshen Ouyang, Gang Cai, Biao Li, Jia Liu, Zhifeng Li, Rong Xiao, Luqun Wang, Yujie Jiang, Yanyan Liu, Xiaoyun Zheng, Pengpeng Xu, Li Wang, Saijuan Chen, Wei-Li Zhao

Haematologica 110(11) 2714-2725

PMID40207715
PMCIDPMC12580706
DOI10.3324/haematol.2025.287513
发表日期2025-04-10
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

The multi-center randomized phase III NHL-004 study compared etoposide, dexamethasone and pegaspargase (ESA) versus the methotrexate, etoposide, dexamethasone and pegaspargase (MESA) regimen, combined with sandwiched radiotherapy, in newly diagnosed early-stage nasal natural killer / T-cell lymphoma (NKTCL). Here we report the long-term outcomes (median follow-up, 64 months) and biomarker analysis. A total of 256 eligible patients aged 14-70 years were randomly assigned (1:1) to the ESA or the MESA arm. The 5-year progression-free survival (PFS) rates were 80.3% and 74.9% in the ESA and MESA arms (hazard ratio [HR]=0.78 [95% CI: 0.46-1.33], P=0.371), and the 5-year overall survival (OS) rates were 85.1% and 80.9% (HR=0.74 [95% CI: 0.40-1.37], P=0.332), respectively. No new safety signals related to treatments were observed. Interim plasma Epstein-Barr virus (EBV) DNA positivity and stable disease / progressive disease response were independent predictors of inferior PFS and OS. No prognostic significance was observed according to molecular subtypes. Interim EBV DNA positivity correlated with up-regulated chromatin remodeling alterations, immune escape-related genes, and decreased infiltrating monocytes / M1 macrophages. With low toxicity, non-intravenous administration, and an outpatient design, ESA with sandwiched radiotherapy achieved long-term durable response in patients with newly diagnosed early-stage NKTCL. Dynamic monitoring of plasma EBV DNA provided a clinical rationale for future mechanism-based therapy in NKTCL.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Figure 1.

Long-term survival in modified intention-to-treat population. (A) Kaplan-Meier survival curve of progression-free survival (PFS) according to treatment arms. (B) Kaplan-Meier survival curve of overall survival according to treatment arms. (C) Forest plot of hazard ratios of PFS for patients with different subgroups, according to treatment arms. CA: Chinese Southwest Oncology Group and Asia Lymphoma Study Group ENKTL system; CI: confidence interval; EBV: Epstein-Barr virus; ECOG: Eastern Cooperative Oncology Group; ESA: etoposide, dexamethasone, and pegaspargase; HR: hazard ratio; IPI: International Prognostic Index; MESA: methotrexate, etoposide, dexamethasone, and pegaspargase; NRI: Nomogram-Revised Risk Index; PINK-E: Prognostic Index of Natural-Killer lymphoma-Epstein-Barr virus; y: years.

A

progression-free survival

Figure 1. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

overall survival

Figure 1. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 2.Progression-free survival and overall survival of Epstein-Barr virus DNA subgroups. Kaplan-Meier survival curve of progression-free survival (PFS) (A) and overall survival (OS) (B) according to pre-treatment Epstein-Barr virus (EBV) DNA. Kaplan-Meier survival curve of PFS (C) and OS (D) according to interim EBV DNA. Kaplan-Meier survival curve of PFS (E) and OS (F) according to post-treatment EBV DNA. CI: confidence interval; HR: hazard ratio.
非 KM Figure
Figure 3.Genetic mutations. (A) Gene mutations landscape. Kaplan-Meier survival curve of progression-free survival (B) and overall survival (C) according to JAK3 mutation. WES: whole exome sequencing; WGS: whole genome sequencing.
非 KM Figure
Figure 4.Transcriptomic signatures. (A) MYC and (B) CD56 expressions according to interim Epstein-Barr virus (EBV) DNA. (C) Differentially expressed genes according to interim EBV DNA. (D) Gene Set Enrichment Analysis revealed differential pathway alterations according to interim EBV DNA. (E) Up-regulated pathways in patients with interim EBV DNA positivity. (F) Infiltration of immune cells between positive and negative interim EBV DNA. NK: natural killer cells.
非 KM Figure